Business context and reporting period
This is Ekso Bionics Holdings, Inc.’s Form 10-K for the fiscal year ended December 31, 2023—not a quarterly filing. The supplied company metadata names Chronoscale Holdings Corp.; that does not match the registrant identified in the filing. The filing reports annual results, not standalone fourth-quarter results.
Ekso designs and sells exoskeletons for medical rehabilitation and industrial use. Its EksoHealth segment includes clinical and personal medical devices; EksoWorks primarily sells the EVO industrial product. The 2022 acquisition of Parker Hannifin’s Human Motion and Control business added the Indego products, which the company integrated during 2023.
Financial performance and condition
Amounts below are in U.S. dollars; financial statement amounts are in millions except per-share data.
| Metric | 2023 | 2022 |
|---|---|---|
| Revenue | $18.279 | $12.912 |
| Gross profit / margin | $9.079 / 50% | $6.214 / 48% |
| Operating loss | $(15.112) | $(15.556) |
| Net loss | $(15.198) | $(15.080) |
| Net loss per share, basic and diluted | $(1.10) | $(1.16) |
| Cash used in operating activities | $(12.054) | $(14.688) |
- Revenue grew 42%, primarily from higher EksoNR and Indego device sales. EksoHealth revenue was $17.702 million; EksoWorks revenue was $0.577 million.
- Gross margin improved by 2 percentage points, which management attributed to lower device costs. Operating expenses rose 11% to $24.191 million, including higher sales and R&D costs associated with the HMC acquisition.
- Cash and restricted cash at year-end was $8.638 million, including $2.0 million restricted under the bank loan covenant; management estimated unrestricted cash of approximately $6.638 million. Working capital was $12.1 million, down from $21.8 million.
- Year-end notes payable included a $2.0 million Pacific Western Bank term loan and a Parker promissory note with $4.688 million of scheduled principal remaining. The bank loan matures in August 2026; Parker note installments run through September 2027. The bank loan is secured by substantially all assets other than intellectual property and has restrictive covenants.
- Contractual obligations were reported as $11.155 million, including debt, leases, and $2.783 million of purchase obligations. The filing’s separate commitments table totals $8.372 million because it excludes those purchase obligations.
Material changes versus the prior comparable period
- Revenue increased $5.367 million (42%); gross profit rose $2.865 million (46%). Higher EksoHealth device volume drove the increases.
- EksoWorks revenue fell $0.5 million, reflecting lower EVO sales, manufacturing-transition delays, and no comparable royalty revenue recognized in 2023.
- Operating cash use improved by $2.634 million, but remained substantial. Cash and restricted cash fell by $11.887 million during 2023.
- Net loss was broadly flat, increasing $0.118 million. The prior-year $1.317 million gain on warrant revaluation became a $0.133 million loss in 2023; foreign exchange moved from a $0.655 million loss to a $0.412 million gain.
- Following year-end, the company sold approximately 2.968 million shares in a January 2024 registered direct offering, generating about $3.910 million in net proceeds.
Outlook, risks and unusual items
- Going concern: The auditor’s report and management state that substantial doubt exists about the company’s ability to continue as a going concern for at least 12 months after issuance of the financial statements. Management expects operating losses and negative operating cash flow and says additional financing is needed; its plans do not alleviate the substantial doubt. The auditor issued an unmodified opinion on the financial statements with a going-concern emphasis.
- Funding and dilution: Management expects continued reliance on external financing and is evaluating financing alternatives. Additional equity financing could dilute shareholders. The January 2024 offering provided approximately $3.9 million net; the filing also reports roughly $4.3 million available under the ATM program.
- Reimbursement: CMS deferred its payment determination for personal exoskeletons on February 29, 2024 and requested additional payer data. No established CMS reimbursement amount exists for these products; approval, timing, and payment levels remain uncertain.
- European certification: Indego Therapy and Indego Personal relied on Parker’s CE certificates, which expire May 25, 2024. Ekso expected to obtain its own certificates in 2024, but the timing was unconfirmed. Failure to transition could interrupt European sales. EksoNR’s EU MDR transition was expected in late 2024.
- Product development: Nomad remained pre-revenue and under development; limited clinical-trial volumes were expected in 2024, with commercial launch planned for 2025. These are plans, not assured outcomes. The filing provides no numeric financial guidance.
- Other risks: The company has a history of significant losses, lengthy sales cycles, dependence on key medical products and third-party distributors, component and manufacturing risks, competition, regulatory and product-liability exposure, foreign-currency risk, and potential further equity dilution. One EksoNR adverse-event report was filed in 2023; the company reported no resulting field action or recall.
- Unusual items: A $0.7 million payment from Parker under a warranty-claim settlement was recorded as deferred revenue and is recognized as services are performed. Management reported effective disclosure controls and internal control over financial reporting; the auditor was not engaged to attest to internal control effectiveness.
Important facts for investors to verify
- Confirm the registrant identity and filing period: this source is Ekso Bionics Holdings, Inc.’s 2023 annual report, not a Chronoscale filing or standalone Q4 report.
- Assess available liquidity after restricted cash, the January 2024 financing, ongoing cash burn, debt service, and the company’s stated going-concern uncertainty.
- Track CMS reimbursement developments and whether Ekso obtains its own European CE certificates before Parker’s certificates expire.
- Review the pace and profitability of EksoHealth growth, the recovery of EVO sales after manufacturing delays, and progress toward Nomad commercialization.
- Check the full debt and contractual-obligation schedules, financing covenants, ATM capacity, and potential dilution from future offerings, warrants, and equity awards.